Hypothesis domain
Therapeutic antibodies
Antibody engineering is a public research and commercial field. Novel Gene does not run antibody campaigns, affinity maturation, or clinical programs.
Public context
Public papers and company websites describe computational antibody design, affinity maturation, and developability screening. Those sources belong to their authors. They are not Novel Gene results.
What Novel Gene is not claiming
- No in-house antibody pipeline, wet lab, or overnight design–build–test cadence.
- No hit-rate, KD, or cycle-time figures.
- No named partners, patients, or clinical claims (clinical claims stay blocked).